Month: April 2025

CALGARY, Alberta, April 29, 2025 (GLOBE NEWSWIRE) — Jura Energy Corporation (“Jura” or the “Company”) (TSXV: JEC) today announced the filing on SEDAR+ of its consolidated annual audited financial statements and management’s discussion and analysis for the years ended December 31, 2024 and 2023, as well as National Instrument 51-101 – Standards of Disclosure for Oil and Gas Activities, Form 51-101F1 Statement of Reserves Data and Other Oil and Gas Information as of December 31, 2024 (the “2024 Reserves Report”). As disclosed previously, Jura’s subsidiaries are involved in ongoing arbitrations (the “PEL Arbitrations”) with Petroleum Exploration (Private) Limited (“PEL”), the operator of the Badin IV North and Badin IV South blocks (together the “Badin Blocks”). Despite a recent award in favour of Jura’s...

TORTOLA, British Virgin Islands, April 29, 2025 (GLOBE NEWSWIRE) —  Orca Energy Group Inc. (“Orca” or “the Company” and includes its subsidiaries and affiliates) (TSX-V: ORC.A, ORC.B) today announced its audited financial results for the fourth quarter (“Q4 2024“) and year ended December 31, 2024. All dollar amounts are in United States dollars unless otherwise stated.Revenue increased by 51% for Q4 2024 and by 1% for the year ended December 31, 2024 compared to the same prior year periods. Certain volumes were supplied as Protected Gas (defined below) prior to July 31, 2024. After the termination of Protected Gas after July 31, 2024, those volumes were instead supplied as Additional Gas (defined below). These volumes, which were delivered to Songas Limited (“Songas“) in August,...

NEW YORK, April 29, 2025 (GLOBE NEWSWIRE) — Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided highlights of its recent activities for the third quarter ended March 31, 2025. “We were very pleased to have made Ryoncil® (remestemcel-L) commercially available to treat children with acute GVHD within one quarter of receiving FDA approval as the first mesenchymal stromal cell (MSC) therapy approved in the US for any indication,” said Dr. Silviu Itescu, CEO of Mesoblast. “With our strong cash position we are well placed to expand Ryoncil® indications to other serious and life-threatening pediatric inflammatory diseases, and to adults with acute GvHD.” FINANCIAL HIGHLIGHTSNet operating cash spend for the quarter was US$12.7 million. Cash on hand at the...

WINDSOR, Ontario, April 29, 2025 (GLOBE NEWSWIRE) — NEXE Innovations Inc. (“NEXE”, the “Company”, “we”, “us” or “our”) (TSX.V: NEXE) (Frankfurt: NX5) (OTC: NEXNF), a compostable and innovative materials company, is pleased to announce its financial results for the three-month period ended February 28, 2025 (“Q3 2025”). We at NEXE Innovations are pleased with the milestones achieved in 2024 and what we believe are the transformative opportunities ahead. As of April 22, 2025, NEXE has delivered over one million pods to our partners, demonstrating continued interest in our products across Canada and the U.S. We are currently focusing our sales efforts on the Canadian market while also advancing our U.S. expansion strategy to better serve customers in that market....

VANCOUVER, British Columbia, April 29, 2025 (GLOBE NEWSWIRE) — Patagonia Gold Corp. (“Patagonia” or the “Company”) (TSXV: PGDC) announces its audited results for the financial year ended December 31, 2024 (“YE 2024”). The audited, consolidated financial statements at year-end 2024, together with the related management’s discussion and analysis, are available on the Company’s website and under the Company’s profile at www.sedarplus.ca. HighlightsGenerated revenue of US$8.8 million in 2024. Produced 2,810 gold equivalent ounces and sold 3,705 gold equivalent ounces (1) from the Cap-Oeste operation in Santa Cruz, Argentina. Spent US$3 million on exploration of key projects in Argentina including completion of:A diamond drilling program in the Abril target to test the extension of mineralization identified in previous reverse circulation...